Janos L. Tanyi, M.D., Ph.D.

faculty photo
Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Attending Physician, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Obstetrics and Gynecology

Contact information
Department of Obstetrics and Gynecology
Jordan Center for Gynecologic Cancer at Penn
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
M.D. (Summa cum Laude)
University of Debrecen, Faculty of Medicine, Hungary , 1993.
Ph.D. (Summa cum Laude)
Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Tanyi JL, Haas AR, Morgan MA, Aggarwal C, O'Hara MH, Lacey SF, Young RM, Sheppard NC, Albelda S, June CH. : Comparing the autologous T cells bearing fully-humanized chimeric antigen receptors (M5) to non-humanized CAR T (SS1) for targeting mesothelin in mesothelin-expressing cancers. Society of Pelvic Surgeon Annual Meeting - Oral Presentation June 2022.

Aznar AM, Good CR, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O’Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH. : Mechanisms of CAR T cell dysfunction and identification of transcription factors that drive the exhaustion phenotype. AACR Annual Meeting - Oral Presentation Apr 2022.

Tanyi JL, Haas AR, Aggarwal C, O'Hara MH, Lacey SF, Golden R, Hwang WT, Young RM, Sheppard NC, Albelda S, June CH. : Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. SGO Annual Meeting - Poster Mar 2022.

Mastroyannis SA, Chen A, Ko E, Facciabene A, Tanyi JL. : Antibiotic exposure around first-line chemotherapy and survival in ovarian cancer. SGO Annual Meeting - Poster Mar 2022.

Jiang J, Yuan J, Hu Z, Zhang Y, Zhang T, Xu M, Long M, Fan Y, Tanyi JL, Montone KT, Tavana O, Vonderheide RH, Chan HM, Hu X, Zhang L.: Systematic illumination of druggable genes in cancer genomes. Cell Rep. Page: 38(8):110400. doi: 10.1016/j.celrep.2022.110400, Feb 2022.

Jiang J, Yuan J, Hu Z, Xu M, Zhang Y, Long M, Fan Y, Montone KT, Tanyi JL, Tavana O, Chan HM, Zhang L, Hu X: Systematic Pan-Cancer Characterization of Nuclear Receptors Identifies Potential Cancer Biomarkers and Therapeutic Targets. Cancer Res Page: 82(1):46-59. doi: 10.1158/0008-5472.CAN-20-3458, Jan 2022.

Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH.: An NK-like CAR T cell transition in CAR T cell dysfunction. Cell Page: 184(25):6081-6100.e26. doi: 10.1016/j.cell.2021.11.016, Dec 2021.

Hu Z, Yuan J, Long M, Jiang J, Zhang Y, Zhang T, Xu M, Fan Y, Tanyi JL, Montone KT, Tavana O, Chan HM, Hu X, Vonderheide RH, Zhang L.: The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer. Page: 2(12):1406-1422. doi: 10.1038/s43018-021-00282-w. Dec 2021.

Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, Casado J, Genolet R, Benedetti F, Wicky A, Ioannidou K, Castro W, Neal C, Moriot A, Renaud-Tissot S, Anstett V, Fahr N, Tanyi JL, Eiva MA, Jacobson CA, Montone KT, Westergaard MCW, Svane IM, Kandalaft LE, Delorenzi M, Sorger PK, Färkkilä A, Michielin O, Zoete V, Carmona SJ, Foukas PG, Powell DJ Jr, Rusakiewicz S, Doucey MA, Dangaj Laniti D, Coukos G: Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell Page: 39(12):1623-1642.e20. doi: 10.1016/j.ccell.2021, Dec 2021.

Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. Page: 163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Nov 2021.

back to top
Last updated: 03/08/2022
The Trustees of the University of Pennsylvania